Literature DB >> 3674852

Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

A Rodríguez1, M V Vicente, T Olay.   

Abstract

The efficacy of fosfomycin in combination with vancomycin or gentamicin was evaluated in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. After 5 days of therapy, both combinations proved to be highly effective since all rabbits had sterile vegetations.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3674852      PMCID： PMC174962          DOI： 10.1128/AAC.31.9.1444

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Comparison of fosfomycin and vancomycin therapy for experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis.

Authors:  A Rodríguez; M V Vicente; T Olay
Journal:  Eur J Clin Microbiol       Date:  1985-12       Impact factor: 3.267

2.  International collaborative study on standardization of bacterial sensitivity to fosfomycin.

Authors:  J M Andrews; F Baquero; J M Beltran; E Canton; F Crokaert; M Gobernado; R Gomez-Ius; E Loza; M Navarro; T Olay
Journal:  J Antimicrob Chemother       Date:  1983-10       Impact factor: 5.790

3.  Automated fluorescence polarization immunoassay for monitoring vancomycin.

Authors:  K S Schwenzer; C H Wang; J P Anhalt
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

4.  Fluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma.

Authors:  M E Jolley; S D Stroupe; C H Wang; H N Panas; C L Keegan; R L Schmidt; K S Schwenzer
Journal:  Clin Chem       Date:  1981-07       Impact factor: 8.327

5.  In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus.

Authors:  S H Guenthner; R P Wenzel
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

6.  Gentamicin- and methicillin-resistant, clinical isolates of Staphylococcus aureus: comparative in vitro and in vivo efficacy of alternative antimicrobial drugs.

Authors:  W H Traub; M Spohr; D Bauer
Journal:  Chemotherapy       Date:  1984       Impact factor: 2.544

7.  Fosfomycin: Laboratory studies.

Authors:  H B Woodruff; J M Mata; S Hernández; S Mochales; A Rodríguez; E O Stapley; H Wallick; A K Miller; D Hendlin
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

8.  In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus.

Authors:  S Alvarez; M Jones; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

9.  Experimental endocarditis caused by Streptococcus sanguis: single and combined antibiotic therapy.

Authors:  M V Vicente; T Olay; A Rodríguez
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

10.  Comparison of a micromethod for performance of the serum bactericidal test with the standard tube dilution method.

Authors:  C G Prober; S S Dougherty; K L Vosti; A S Yeager
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191
  10 in total
  7 in total

Review 1.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

2.  Efficacy of ampicillin plus arbekacin in experimental rabbit endocarditis caused by an Enterococcus faecalis strain with high-level gentamicin resistance.

Authors:  V Kak; S M Donabedian; M J Zervos; R Kariyama; H Kumon; J W Chow
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

3.  Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin.

Authors:  Q Mei; Y Ye; Y-L Zhu; J Cheng; X Chang; Y-Y Liu; H-R Li; J-B Li
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-26       Impact factor: 3.267

4.  Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa.

Authors:  David L MacLeod; Jyoti Velayudhan; Thomas F Kenney; Joseph H Therrien; Jennifer L Sutherland; Lynn M Barker; William R Baker
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

5.  Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin.

Authors:  M E Pachón-Ibáñez; S Ribes; M A Domínguez; R Fernández; F Tubau; J Ariza; F Gudiol; C Cabellos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-16       Impact factor: 3.267

6.  Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.

Authors:  Nathalie Asseray; Cedric Jacqueline; Virginie Le Mabecque; Eric Batard; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

7.  Low efficacy of tobramycin in experimental Staphylococcus aureus endocarditis.

Authors:  C J Lerche; L J Christophersen; H Trøstrup; K Thomsen; P Ø Jensen; H P Hougen; H Bundgaard; N Høiby; C Moser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-10-06       Impact factor: 3.267
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.